Research materials for laboratory use only

Free UK delivery from £25 · Same-day dispatch · Tracked European delivery

Customer support
Peptide

Retatrutide research pen 20 mg / 40 mg total contents

The Zynx Retatrutide research pen uses a dual-chamber format, with 20 mg or 40 mg total contents per pen. UK and European delivery options are listed below.

Choose your pen

Total contents per pen

Product total£110.00£110.00 per pen

Speak with our team about your research order

Ordering for a laboratory? Ask about bulk orders of 100 pens or more.

Add your selection to the basket to include the strength and quantity in your order enquiry.
Zynx Healthcare

Telegram enquiry

Copy your enquiry and send it to our team through the contact page.

Contact the team

How the dual-chamber peptide pen works · Retatrutide research explained

What do 20 mg and 40 mg mean on a Retatrutide pen?

Supplied for laboratory and scientific research only. Not for human or veterinary use.

  • Free UK delivery from £25
  • Same-day dispatch
  • Tracked European delivery
  • Order tracking provided

Same-day dispatch on eligible in-stock orders

Order now for dispatch on the next working day

UK and European delivery · Quality documentation · Support

Fast, tracked delivery

Free UK delivery when you spend £25 or more. Eligible in-stock orders are dispatched the same working day, with tracked delivery available to selected European destinations.

Delivery estimate

Method
Free UK tracked delivery
Charge
Free
Dispatch
Mon, 9 Nov 2026
Delivery window
Estimated delivery Tue, 10 Nov 2026–Thu, 12 Nov 2026

Delivery windows are estimates, not guarantees. Dispatch is not the same as delivery.

Retatrutide 20 mg vs 40 mg: prices and contents

Compare the current price and stated total contents of one pen. Unit prices use the labelled total mass; delivery charges depend on the destination and order.

Total contents, prices and product codes
Specification20 mg total per pen40 mg total per pen
Product code (SKU)ZX-RETA-20ZX-RETA-40
Price per pen£110.00£130.00
Price per stated mg£5.50£3.25
AvailabilityIn stockIn stock
FormatDual-chamber research penDual-chamber research pen

For the meaning of these amounts, read Retatrutide 20 mg and 40 mg pens: contents explained. The listed amount is a product specification; it does not establish a batch test result.

Batch-report availability: No Retatrutide batch reports are currently published on this website. Check the batch-document library and read the peptide CoA guide.

Product specifications

NameRetatrutide
CategoryPeptide
Listed amount20 mg total per pen
SKUZX-RETA-20
FormatDual-chamber research pen
ClassificationSupplied for laboratory and scientific research only. Not for human or veterinary use.
DispatchSame-day dispatch on eligible in-stock orders

Shipping and support

Free UK delivery when you spend £25 or more. Eligible in-stock orders are dispatched the same working day, with tracked delivery available to selected European destinations.

Choose your country at checkout to confirm product availability and delivery charges.

Delivery windows are estimates, not guarantees. Dispatch is not the same as delivery, and customs clearance is not controlled by Zynx.

Documentation

Supporting quality documentation is displayed where available.

Quality and batch documentation · Verify a product code · Research-use policy · Delivery · Returns. Published reports are listed on the quality page against the matching product and batch.

Assessing research material? Read the peptide CoA checklist · Understand purity, identity and content · Check code and batch traceability.

Research references

Published papers describe research on the named compound or related molecules. They do not test, certify or endorse the specific material shown on this page, and they do not make the material approved for personal use.

For help comparing the populations, time points and outcomes below, read Retatrutide phase 2 vs phase 3: how to compare trial results.

Published trials describe study materials and groups. They do not identify a Zynx batch, and they are not a certificate for a product on this website.

Human randomised trial

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1)

New England Journal of Medicine, 2026

Trial stage
Phase 3 randomised trial
Participants
2,339 adults with obesity without diabetes
Duration
80 weeks
What was measured
Body-weight change. The 12 mg arm averaged −25.0% versus −3.9% with placebo using the treatment-regimen analysis.

A trial average is not an individual prediction. The trial material was not a Zynx product; the study does not certify or endorse Zynx materials.

Human randomised trial

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a phase 3 trial

The Lancet, 2026

Trial stage
Phase 3 randomised trial
Participants
1,152 adults with obesity and type 2 diabetes
Duration
80 weeks
What was measured
Body-weight change. The 12 mg arm averaged −18.8% versus −5.1% with placebo using the treatment-regimen analysis.

This was a separate population and trial from TRIUMPH-1. Results cannot be directly compared as treatment effects, and no Zynx material was tested.

Human randomised trial

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

New England Journal of Medicine, 2023

Trial stage
Phase 2 randomised trial
Participants
338 adults with obesity
Duration
48 weeks
What was measured
Body weight. The 12 mg trial arm averaged a 24.2% reduction, compared with 2.1% with placebo.

The trial did not test or validate any Zynx product. It does not identify a Zynx batch.

Human randomised trial

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

The Lancet Diabetes & Endocrinology, 2025

Trial stage
Phase 2 body-composition substudy
Participants
189 adults with type 2 diabetes
Duration
36-week assessment
What was measured
Total fat mass by DXA. The pooled 8 mg arms fell 26.1% from baseline, compared with 4.5% with placebo.

This substudy of an investigational medicine did not test any Zynx pen. It does not establish long-term clinical benefit or product safety.

Human randomised trial

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Nature Medicine, 2024

Trial stage
Phase 2a randomised trial
Participants
98 adults with metabolic dysfunction-associated steatotic liver disease
Duration
24-week assessment
What was measured
Liver fat by MRI. Mean relative liver fat fell 81.4% from baseline in the 8 mg arm, versus a 0.3% increase with placebo.

The investigational trial did not test any Zynx product and cannot validate the quality, safety or effect of a Zynx pen.

Product questions

Useful context

How is Retatrutide supplied?

Retatrutide is supplied as a dual-chamber research pen, with 20 mg or 40 mg total contents per pen. These are total contents, not administration instructions. For laboratory research only.

What is the difference between the 20 mg and 40 mg Retatrutide pens?

The 40 mg option has twice the stated total contents of the 20 mg option. Both are listed as dual-chamber research pens. Compare their current per-pen prices, price per stated milligram, product codes and availability in the options table. The total-content figure does not establish concentration or purity.

Is reta another name for Retatrutide?

Reta is informal shorthand for Retatrutide, also identified as LY3437943 in research literature. Zynx uses the full compound name, Retatrutide, on this product page.

Can I order Retatrutide research pens for UK delivery?

UK delivery is available for eligible orders. Select the 20 mg or 40 mg total-content option above to see its current price and availability. The delivery calculator shows the options for your destination; final delivery charges are confirmed at checkout. These materials are supplied for laboratory research only.

Is this a pre-mixed pen or a dual-chamber pen?

Zynx supplies a dual-chamber research pen. The research material and liquid are held in separate chambers within the cartridge, rather than together as a pre-mixed solution. The format guide explains the cartridge design; product documentation provides the specific handling requirements.

Do the published trials describe a Zynx batch?

No. The papers report controlled studies. They do not test a Zynx batch and they are not a laboratory report for a product on this site.